Core Insights - The company has successfully developed a liquid chip platform that addresses a critical technology bottleneck in the in vitro diagnostic (IVD) field, previously dominated by foreign giants [1][2][3] - The liquid chip technology is recognized as a key area for innovation in China's "13th Five-Year" national science and technology plan, highlighting its importance for future diagnostic advancements [2] - The platform has been implemented in several renowned hospitals in Shanghai and the Southwest region, providing reliable diagnostic support for tumor markers and autoimmune diseases [1][7] Technology and Innovation - The liquid chip technology utilizes special fluorescent polymer microspheres and signal analysis, overcoming high technical barriers that have historically limited domestic capabilities [2][3] - The core breakthrough involves the use of quantum dot materials for microsphere encoding, allowing for the analysis of over 100 coding signals and enhancing the capacity to thousands with 3D encoding technology [2][4] - The company has established a comprehensive intellectual property system covering the entire supply chain from raw materials to end instruments and reagents, eliminating reliance on foreign technologies [3][4] Product Development and Market Expansion - The company has launched the Mplex-MA1600, the first dual-function immunoassay analyzer in the industry, integrating flow fluorescence and chemiluminescence technologies for efficient multi-item and rapid single-item testing [4][5] - Since July 2023, the company has received 13 NMPA registration certificates for reagents in various fields, including tumor markers and autoimmune diseases, with plans to expand the range of detectable markers [5][6] - The liquid chip technology is also being applied in animal testing and food safety, with collaborations with several research institutes to develop diagnostic kits for various pathogens in livestock [6][7] Competitive Advantage - The company has achieved a breakthrough in "higher performance and lower cost" compared to international leader Luminex, thanks to its fully controllable domestic platform [1][7] - The new detection system combines quantum dot encoding microspheres with single-laser detection technology, achieving high throughput (120 samples/hour), high sensitivity (pg/mL level), and high accuracy (CV < 5%) [7] - The compact design of the fully automated detection equipment reduces the footprint by approximately 40% and lowers overall detection costs by about 50%, facilitating widespread adoption [7]

Group 1 - The animal vaccine sector increased by 1.35%, ranking fourth among concept sectors, with 13 stocks rising, including Kexing Pharmaceutical, Kanghua Biological, and Dongfang Biological, which rose by 7.40%, 6.06%, and 5.85% respectively [1][2] - The leading stocks in terms of net inflow of main funds include Tiankang Biological with a net inflow of 17.69 million, followed by Dongfang Biological, Dabeinong, and Haizheng Pharmaceutical with net inflows of 17.19 million, 7.87 million, and 5.25 million respectively [2][3] - The main fund inflow rates for Dongfang Biological, Haili Biological, and *ST Xianfeng are 9.15%, 6.15%, and 5.51% respectively [3] Group 2 - The top gainers in the animal vaccine sector include Kexing Pharmaceutical with a rise of 7.40% and Kanghua Biological with a rise of 6.06%, while the biggest losers include Weilan Biological, Jinhai Biological, and Plai Ke, which fell by 1.82%, 1.26%, and 1.08% respectively [1][4] - The overall net outflow of main funds from the animal vaccine sector was 4.75 million, indicating a mixed sentiment among investors [2]

一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 28 日 （二） 股东大会召开的地点：浙江省湖州市安吉县递铺街道阳光大道东段东方 基因会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 证券代码：688298 证券简称：东方生物 公告编号：2025-023 浙江东方基因生物制品股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 | 1、出席会议的股东和代理人人数 | 85 | | --- | --- | | 普通股股东人数 | 85 | | 2、出席会议的股东所持有的表决权数量 | 99,235,127 | | 普通股股东所持有表决权数量 | 99,235,127 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 51.3649% | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 51.3649% | ...

国浩律师（杭州）事务所 关 于 浙江东方基因生物制品股份有限公司 2024 年年度股东大会 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二五年五月 国浩律师（杭州）事务所 法律意见书 国浩律师（杭州）事务所 关 于 浙江东方基因生物制品股份有限公司 2024 年年度股东大会 法律意见书 致：浙江东方基因生物制品股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）接受浙江东方基因生物制品 股份有限公司（以下简称"公司"）委托，指派律师出席公司 2024 年年度股东 大会（以下简称"本 ...

Core Insights - The company is strategically positioning itself in the respiratory testing market by leveraging its expertise in infectious disease detection and expanding its product offerings through multi-detection technology and global market channels [1][5] Group 1: Product Development and Recognition - The Healgen triple detection reagent and H5N1 diagnostic reagent have received significant recognition from Emory University, showcasing their superior performance [2] - Healgen's triple detection reagent is the first to obtain the FDA De Novo certification, marking a milestone for Chinese companies in the high-end IVD market [2] - The company has developed a five-in-one detection reagent for COVID-19, influenza A/B, respiratory syncytial virus, and adenovirus, which has received EU IVDR certification [3] Group 2: Global Market Expansion - The company has achieved FDA 510(k) certification for various detection products in the U.S. and multiple IVDR certifications in Europe, indicating a robust product matrix [4] - The company is implementing a dual-channel strategy by promoting both professional and home testing products, significantly expanding its market reach [4] Group 3: Investment and R&D - The company has invested heavily in clinical trials, with costs around $5 million in the U.S. and €200,000 in Europe, which is notable in the industry [5] - The company has obtained 126 certifications for various respiratory pathogens across multiple countries, establishing a comprehensive global testing framework [5]

一、境外医疗器械注册证的具体情况 二、境内医疗器械注册证的具体情况 | | | | | | 本产品用于体外定量检测人 | | | | --- | --- | --- | --- | --- | | | | 体血清中甲胎蛋白（AFP）的 | | | | | 国械注准 | 含量。用于对恶性肿瘤患者 | 2025/5/14 | | | 甲胎蛋白检测试剂盒 | | 进行动态监测以辅助判断疾 | | 上海万子 | | (流式荧光发光法) | 2025340093 | 病进程或治疗效果，不能作 | - | 健生物 | | | 4 | | 2030/5/13 | | | | | 为恶性肿瘤早期诊断或确诊 | | | | | | 的依据，不宜用于普通人群 | | | | | | 的肿瘤筛查。 | | | 证券代码：688298 证券简称：东方生物 公告编号：2025-022 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证及获得中国合格评定国家 认可委员会（CNAS）实验室认可证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承 ...

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

| 我的感觉是 双 | | | | | | | 清镜入关键词 | | | 2025年5月11日 星期日 O 型染 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | | △ 单报投诉 | | 网站首页 | 法院概况 | | 法院新闻 | | 诉讼服务 | | 审务公开 | 执行信息 | | 权威发布 | | △ 当前位置: 首页>法院公告 > 开庭公告 | | | | | | | | | | | | 法院公告 | 开庭公告 | | | | | | | | | | | + 开庭公告 | | 法院; 全部 | | | 4 | 品血Y: | 浙江东方基因生物制品股份 | 搜 索 | | | | ▶ 减刑假释 | 品展 | 19.000 | 开盘日期 | 排期日期 | ж号 | ਡਰ | 审判长/主审人 | 公语人/重告/上 诉人/申请人 | 被告/被告人/被上诉 人/被申请人 | | | ▶ 破产公告 | 湖州市中 极人民法 R | 第十一选 B | 2025-05-15 0 9:00:0 ...

浙江东方基因生物制品股份有限公司 2024 年年度股东大会 证券简称：东方生物 证券代码：688298 浙江东方基因生物制品股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 28 日 1 浙江东方基因生物制品股份有限公司 2024 年年度股东大会 浙江东方基因生物制品股份有限公司 2024 年年度股东大会会议须知 为维护浙江东方基因生物制品股份有限公司（以下简称"公司"）全体股东 的合法权益，确保股东大会的正常秩序和议事效率，保证股东大会如期、顺利召 开，根据《中华人民共和国公司法》《中华人民共和国证券法》《浙江东方基因 生物制品股份有限公司章程》《浙江东方基因生物制品股份有限公司股东大会议 事规则》等相关规定，特制定本股东大会会议须知。 一、为保证本次股东大会的严肃性和正常秩序，切实维护与会股东（或股东 代表）的合法权益，除出席会议的股东（或股东代表）、公司董事、监事、高级 管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他人员进入会 场。 二、出席会议的股东（或股东代表）须在会议召开前 30 分钟到会议现场办 理签到手续，并按股东大会通知的相关要求，出示自然人股东和法人股东相 ...

5月6日，东方生物今日收盘22.24元，上涨1.37%，最新市净率0.69，总市值44.84亿元。 截至2025年一季报，共有9家机构持仓东方生物，其中其他4家、基金4家、社保1家，合计持股数 11095.58万股，持股市值28.74亿元。 浙江东方基因生物制品股份有限公司专业从事体外诊断产品的研发、生产与销售。公司主要产品有：上 游的抗原/抗体、引物、探针、微球等生物原料，中游的免疫诊断平台（胶体金、荧光免疫、酶联免 疫）、分子诊断平台（PCR核酸+FISH荧光原位杂交）、液态生物芯片平台、生化诊断平台相关的诊断 试剂以及配套诊断仪器，以及下游第三方独立检测实验室等构。公司是极少数从"检测试剂+检测设备 提供商"向"生物原料+检测试剂+检测设备提供商"+"第三方独立检测实验室"的全产业链布局的企业。截 至2023年6月底，累计获得授权专利/软著合计639项，境内268项，境外335项，软件著作权36项，其中 发明专利37项。 最新一期业绩显示，2025年一季报，公司实现营业收入1.92亿元，同比4.94%；净利润-115452483.95 元，同比-71.41%，销售毛利率27.36%。 序号股票简称PE( ...